Ceramides: Shared Lipid Biomarkers of Cardiovascular Disease and Schizophrenia
INTRODUCTION: Schizophrenia, although a debilitating mental illness, greatly affects individuals physical health as well. One of the leading somatic comorbidities associated with schizophrenia is cardiovascular disease, which has been estimated to be one of the leading causes of excess mortality in...
Guardado en:
Autores principales: | Anna I. Tkachev, Elena A. Stekolshchikova, Anna Yu. Morozova, Nikolay A. Anikanov, Yana A. Zorkina, Polina N. Alekseyeva, Elena B. Khobta, Denis S. Andreyuk, Svetlana A. Zozulya, Alexandra N. Barkhatova, Tatiana P. Klyushnik, Alexander M. Reznik, Georgiy P. Kostyuk, Philipp E. Khaitovich |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Eco-Vector
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/469e7b26d5674e168ba9c2677ee37fea |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Plasma Ceramides Pathophysiology, Measurements, Challenges, and Opportunities
por: Melania Gaggini, et al.
Publicado: (2021) -
Ceramide Remodeling and Risk of Cardiovascular Events and Mortality
por: Linda R. Peterson, et al.
Publicado: (2018) -
Periplocymarin Alleviates Doxorubicin-Induced Heart Failure and Excessive Accumulation of Ceramides
por: Weijing Yun, et al.
Publicado: (2021) -
Effects of Wine and Tyrosol on the Lipid Metabolic Profile of Subjects at Risk of Cardiovascular Disease: Potential Cardioprotective Role of Ceramides
por: Jose Rodríguez-Morató, et al.
Publicado: (2021) -
Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Daniela Maria Tanase, et al.
Publicado: (2021)